Klea Holding Expands into Healthcare with Klea Pharmaceuticals

Paris-based KLEA HOLDING has announced the creation of Klea Pharmaceuticals to expand its presence in the healthcare sector. This strategic move aims to market licensed medicines in the rapidly growing Middle Eastern and African markets. The company is leveraging its success with Smart Salem, a network of digital medical testing centres accredited by the Dubai Health Authority, to drive this expansion.

Klea Pharmaceuticals, based in Dubai, will manage a portfolio of 59 registered medicines, targeting both public and private markets. The operation is supported by a robust distribution network and partnerships with Contract Development and Manufacturing Organisations (CDMOs). The pharmaceutical market in the MEA region is valued at $32.6 billion, growing at 7.8% annually, presenting significant opportunities.

The company plans to expand into Saudi Arabia and West Africa by 2027, with further portfolio enhancements. Initial financing of AED 12.5 million will support asset acquisition and working capital needs, ensuring non-dilutive funding for shareholders.